10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424
5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560
DepoCyt® / DepoCyte® (cytarabine liposome injection) is a sustained-release formulation of the chemotherapeutic agent, cytarabine, and is administered once every two weeks.
DepoCyt is marketed in the United States by Enzon Pharmaceuticals and DepoCyte is marketed in Europe by Mundipharma and its independent associated companies.
DepoCyt(e) uses our novel sustained-release delivery technology, DepoFoam® to:
- Allow for the slow and consistent release of cytarabine for the treatment of lymphomatous meningitis
- Ensure uniform distribution and an extended half-life
- Produce reliable, steady, and prolonged drug release
- Reduces administration from twice a week to once every two weeks
DEPOCYT HIGHLIGHT:
LYMPHOMATOUS MENINGITIS
Lymphomatous meningitis (LM) is cancer that started as primary lymphoma and has spread to the lining of the spinal cord and brain (this lining is the meninges). LM is reported in 5-15% of patients with diffuse high-grade non-Hodgkin’s lymphoma.
LM is rarely curable. However, research has shown that treatment that starts soon after the disease is detected can help many patients. In some patients, early treatment can prevent or slow worsening of symptoms caused by growth of cancer in the meninges.